{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:11:29Z","timestamp":1771333889972,"version":"3.50.1"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,25]],"date-time":"2006-01-25T00:00:00Z","timestamp":1138147200000},"content-version":"vor","delay-in-days":2125,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2000,4]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> The development of GnRH\u2010a (analogues or agonists) is a major leap forward in the treatment of various hormone\u2010dependent diseases in medicine. Their introduction in reproductive endocrinology, in <jats:italic>in vitro<\/jats:italic> fertilization\/embryo transfer (IVF\/ET) and other assisted reproduction techniques had a revolutionary impact. They have been effective in other gynecologic conditions including fibroids, endometriosis, anovulatory disorders, precocious puberty, dysfunctional uterine bleeding, and operative hysteroscopy. Medical castration induced by GnRH\u2010a has become first\u2010line therapy in metastatic breast cancer. Their long\u2010term use, though, has been associated with a variety of adverse effects such as bone loss and decreased cardioprotection. \u201cSteroid add\u2010back\u201d therapy in these cases apparently is an effective alternative. It may allow their safe long\u2010term application beyond 6 months, averting unpleasant side\u2010effects and maintaining bone mass and cardioprotection.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2000.tb06258.x","type":"journal-article","created":{"date-parts":[[2010,7,20]],"date-time":"2010-07-20T17:45:27Z","timestamp":1279647927000},"page":"435-443","source":"Crossref","is-referenced-by-count":6,"title":["Current and Potential Application of GnRH Agonists in Gynecologic Practice"],"prefix":"10.1111","volume":"900","author":[{"given":"JOHN M.","family":"TZAFETTAS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,25]]},"reference":[{"key":"e_1_2_10_2_2","first-page":"4","article-title":"Leuproelin, an exciting development in the treatment of gynaecological disorders","volume":"1","author":"Niesert S.","year":"1996","journal-title":"Hormone Ther. Obstet. Gynecol."},{"key":"e_1_2_10_3_2","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1093\/oxfordjournals.humrep.a136219","article-title":"Development and applications of LHRH antagonists in the treatment of infertility: an overview","volume":"10","author":"Reissman T.","year":"1995","journal-title":"Hum Reprod."},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)53639-5"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.76.1.162"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1998.tb09967.x"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)59966-X"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/09513599509160454"},{"key":"e_1_2_10_9_2","first-page":"377","article-title":"Hyalinization and cellular changes in uterine leiomyomata after GnRH\u2010a therapy","volume":"39","author":"Cohen D.","year":"1994","journal-title":"J. Reprod. Med."},{"key":"e_1_2_10_10_2","first-page":"388","article-title":"The secretion of IGF\u2010I and II by explant cultures of fibroids and myometrium from women treated with GnRH agonist","volume":"76","author":"Rein M.S.","year":"1990","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036270"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)55863-4"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)57554-2"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a135960"},{"key":"e_1_2_10_15_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0015-0282(16)56571-6","article-title":"The hypothalamic\u2010pituitary\u2010ovarian axis in patients with endometriosis, is suppressed by leuprolide acetate but not by danazol","volume":"61","author":"Sakata M.","year":"1994","journal-title":"Fertil. Steril."},{"key":"e_1_2_10_16_2","unstructured":"Varcellini P. A. Pisacreta O. De Giorgiet al.1998. Management of advanced endometriosis.In Fertilityand Reproductive Medicine. R.D. Kempers J. Cohen A.F. Haney & J.B. Younger Eds.: 369\u2013386. Excerpta Medica."},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(93)90126-4"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(11)91718-9"},{"key":"e_1_2_10_19_2","first-page":"4","article-title":"Leuprorelin: increasing its role in the management of endometriosis","volume":"2","author":"Filicori M.","year":"1997","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1994.tb13677.x"},{"key":"e_1_2_10_21_2","first-page":"351","article-title":"Revised American Fertility Society classification of endometriosis: 1995","volume":"43","author":"American Fertility Society","year":"1995","journal-title":"Fertil. Steril."},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000291819"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)59062-1"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.3109\/00016349009013304"},{"key":"e_1_2_10_25_2","first-page":"574","article-title":"Endometrial ablation in the treatment of excessive uterine bleeding","volume":"6","author":"Ke R.W.","year":"1991","journal-title":"Hum. Reprod."},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a137105"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(94)90291-7"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0897.1994.tb01129.x"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1994.tb13584.x"},{"key":"e_1_2_10_30_2","unstructured":"Royal College of Obstetricians and Gynaecologists. 1998. The management of recurrent miscarriage. Guideline No 17. London UK."},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.humrep.a138714"},{"key":"e_1_2_10_32_2","unstructured":"Emons G. O. Ortmann & K.D. Schulz. 1996. GnRH\u2010a in ovarian breast and endometrial cancer.InGnRH Analogues The State of the Art 1996. B. Lunenfeld & V. Insler Eds.: 95\u2013120. Parthenon Publishing. Carnforth. UK."},{"key":"e_1_2_10_33_2","first-page":"97","article-title":"Clinical and endocrine effects of leuprorelin acetate in pre and post\u2010menopausal patients with advanced breast canbdr","volume":"14","author":"Dowsett M.","year":"1992","journal-title":"Clif. Ther."},{"key":"e_1_2_10_34_2","unstructured":"Emons G. O. Ortmann G. Irmeret al.1996. Treatment of ovarian cancer with LH\u2010RH antagonists.InTreatment with GnRH\u2010a: Controversies and Perspectives. M. Filicori & C. Flamigni Eds.: 165\u2013172. Parthenon. Carnforth. UK."},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-88-470-2186-0_7"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod52.2.365"},{"key":"e_1_2_10_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)90667-V"},{"key":"e_1_2_10_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(92)91706-G"},{"key":"e_1_2_10_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(97)02733-4"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)59763-5"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)56090-7"},{"key":"e_1_2_10_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(98)00022-3"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1998.tb10146.x"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2000.tb06258.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2000.tb06258.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T15:41:10Z","timestamp":1695656470000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2000.tb06258.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,4]]}},"alternative-id":["10.1111\/j.1749-6632.2000.tb06258.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06258.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,4]]}}}